Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Пирибедил в лечении когнитивных нарушений
Пирибедил в лечении когнитивных нарушений
Копишинская С.В., Светозарский С.Н. Пирибедил в лечении когнитивных нарушений. Неврология и Ревматология (Прил. к журн. Consilium Medicum). 2018; 2: 15–19.
DOI: 10.26442/2414357X.2018.2.000031
DOI: 10.26442/2414357X.2018.2.000031
DOI: 10.26442/2414357X.2018.2.000031
________________________________________________
DOI: 10.26442/2414357X.2018.2.000031
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
К когнитивным функциям относят внимание, речь, интеллект, восприятие, праксис, память. Нарушение когнитивных функций снижает трудоспособность, развитие деменции приводит к инвалидизации и необходимости ухода за пациентом. Совершенствование диагностики, выявление биомаркеров доклинической стадии ряда заболеваний позволяет начать коррекцию когнитивного статуса на стадии легких и умеренных когнитивных нарушений. Формирование доказательной базы в отношении таких немедикаментозных методов лечения, как музыкотерапия, физические упражнения, компьютеризированный когнитивный тренинг, расширяет возможности врача в лечении когнитивных нарушений. Нейрохимия определяет направления развития когнитивной фармакологии, устанавливая патогенетически ориентированные точки приложения в центральной нервной системе. Препаратом, обладающим сродством к дофаминергическим и норадренергическим рецепторам, является пирибедил (Проноран). В настоящее время пирибедил широко применяется как для коррекции моторных и немоторных проявлений болезни Паркинсона, так и при синдроме легких и умеренных когнитивных нарушений. Высокая эффективность и безопасность препарата доказаны в ряде отечественных и зарубежных клинических исследований.
Ключевые слова: когнитивные функции, синдром умеренных когнитивных нарушений, Проноран, дофамин.
Key words: cognitive functions, mild cognitive impairment, Pronoran, dopamine.
Ключевые слова: когнитивные функции, синдром умеренных когнитивных нарушений, Проноран, дофамин.
________________________________________________
Key words: cognitive functions, mild cognitive impairment, Pronoran, dopamine.
Полный текст
Список литературы
1. Захаров В.В. Распространенность и лечение когнитивных нарушений в неврологической клинике (результаты всероссийского исследования "ПРОМЕТЕЙ"). Consilium Medicum. 2008; 10 (2): 114–8. / Zakharov V.V. Rasprostranennost' i lechenie kognitivnykh narushenii v nevrologicheskoi klinike (rezul'taty vserossiiskogo issledovaniia "PROMETEI"). Consilium Medicum. 2008; 10 (2): 114–8. [in Russian]
2. Allain H, Akwa Y, Lacomblez L et al. Impaired cognition and attention in adults: pharmacological management strategies. Neuropsychiatr Dis Treat 2007; 3 (1): 103–16. DOI: 10.2147/nedt.2007.3.1.103
3. Kirova AM, Bays RB, Lagalwar S. Working memory and executive function decline across normal aging, mild cognitive impairment, and Alzheimer's disease. Biomed Res Int 2015; 2015: 748212. DOI: 10.1155/2015/748212
4. Яхно Н.Н., Захаров В.В. Легкие когнитивные нарушения в пожилом возрасте. Неврол. журн. 2004; 1: 4–8. / Iakhno N.N., Zakharov V.V. Legkie kognitivnye narusheniia v pozhilom vozraste. Nevrol. zhurn. 2004; 1: 4–8. [in Russian]
5. Гехт И.А., Артемьева Г.Б. Постарение населения и программы модернизации здравоохранения. Клин. геронтология. 2013; 19 (7–8): 37–8. / Gekht I.A., Artem'eva G.B. Postarenie naseleniia i programmy modernizatsii zdravookhraneniia. Klin. gerontologiia. 2013; 19 (7–8): 37–8. [in Russian]
6. Wimo A, Guerchet M, Ali G et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement 2017; 13 (1): 1–7. DOI: 10.1016/j.jalz.2016.07.150
7. Владимирова О.Н., Башкирёва А.С., Коробов М.В. и др. Медико-социальные аспекты первичной инвалидности у лиц трудоспособного и старше трудоспособного возраста в Российской Федерации. Успехи геронтологии. 2017; 30 (4): 498–504. / Vladimirova O.N., Bashkireva A.S., Korobov M.V. i dr. Mediko-sotsial'nye aspekty pervichnoi invalidnosti u lits trudosposobnogo i starshe trudosposobnogo vozrasta v Rossiiskoi Federatsii. Uspekhi gerontologii. 2017; 30 (4): 498–504. [in Russian]
8. Смирнов А.А., Густов А.В., Копишинская С.В., Антонова В.А. Преддементные состояния и деменция у лиц молодого возраста. Неврология, нейропсихиатрия, психосоматика. 2014; 2: 41–3. / Smirnov A.A., Gustov A.V., Kopishinskaia S.V., Antonova V.A. Preddementnye sostoianiia i dementsiia u lits molodogo vozrasta. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2014; 2: 41–3. [in Russian]
9. Радюк М.А., Светозарский С.Н., Копишинская С.В. Немоторные проявления болезни Паркинсона. Мед. альманах. 2014; 33 (3): 54–8. / Radiuk M.A., Svetozarskii S.N., Kopishinskaia S.V. Nemotornye proiavleniia bolezni Parkinsona. Med. al'manakh. 2014; 33 (3): 54–8. [in Russian]
10. Petersen SE, Sporns O. Brain Networks and Cognitive Architectures. Neuron 2015; 88 (1): 207–19. DOI: 10.1016/j.neuron.2015.09.027
11. Salavati B, Rajji TK, Price R et al. Imaging-Based Neurochemistry in Schizophrenia: A Systematic Review and Implications for Dysfunctional Long-Term Potentiation. Schizophr Bull 2015; 41 (1): 44–56. DOI: 10.1093/schbul/sbu132
12. Захаров В., Милованова О., Гришина Д. и др. Пирибедил в лечении легких и умеренных когнитивных нарушений. Врач. 2017; 3: 32–7. / Zakharov V., Milovanova O., Grishina D. i dr. Piribedil v lechenii legkikh i umerennykh kognitivnykh narushenii. Vrach. 2017; 3: 32–7. [in Russian]
13. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectrums 2014; 19 (2): 121–33. DOI: 10.1017/S1092852913000540
14. Braga AC, Carreiro LRR, Tafla TL et al. Cognitive and behavioral profile of Williams Syndrome toddlers. Codas 2018; 30 (4): e20170188. DOI: 10.1590/2317-1782/
20182017188
15. Whitton L, Apostolova G, Rieder D et al. Genes regulated by SATB2 during neurodevelopment contribute to schizophrenia and educational attainment. PLoS Genet 2018; 14 (7): e1007515. DOI: 10.1371/journal.pgen.1007515
16. Callier SL, Bonham VL. Taking a Stand: The Genetics Community's Responsibility for Intelligence Research. Hastings Cent Rep 2015; 45 (Suppl. 5): S54-8. DOI: 10.1002/hast.500
17. Roberts D. Can Research on the Genetics of Intelligence Be "Socially Neutral"? Hastings Cent Rep 2015; 45 (Suppl. 5): S50-3. DOI: 10.1002/hast.499
18. Aridi YS, Walker JL, Wright ORL. The Association between the Mediterranean Dietary Pattern and Cognitive Health: A Systematic Review. Nutrients 2017; 9 (7): 674. DOI: 10.3390/nu9070674
19. Захаров В.В., Вахнина Н.В., Громова Д.О. и др. Клинический спектр недементных когнитивных расстройств: субъективные, легкие и умеренные нарушения. Неврология, нейропсихиатрия, психосоматика. 2015; 7 (4): 83–91. / Zakharov V.V., Vakhnina N.V., Gromova D.O. i dr. Klinicheskii spektr nedementnykh kognitivnykh rasstroistv: sub"ektivnye, legkie i umerennye narusheniia. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2015; 7 (4): 83–91. [in Russian]
20. Пилипович А.А. Умеренные когнитивные расстройства: роль Пронорана в их коррекции. Consilium Medicum. 2017; 19 (2.3. Неврология и Ревматология): 38–42. / Pilipovich A.A. Moderate cognitive disorders: the role of Pronoran in their correction. Consilium Medicum. 2017; 19 (2.3. Neurology and Rheumatology): 38–42. [in Russian]
21. Светозарский С.Н., Копишинская С.В. Оптическая когерентная томография сетчатки при нейродегенеративных заболеваниях (обзор). Соврем. технол. в мед. 2015; 7 (1): 116–23. / Svetozarskii S.N., Kopishinskaia S.V. Opticheskaia kogerentnaia tomografiia setchatki pri neirodegenerativnykh zabolevaniiakh (obzor). Sovrem. tekhnol. v med. 2015; 7 (1): 116–23. [in Russian]
22. Coyle H, Traynor V, Solowij N. Computerized and virtual reality cognitive training for individuals at high risk of cognitive decline: systematic review of the literature. Am J Geriatr Psychiatry 2015; 23 (4): 335–59. DOI: 10.1016/j.jagp.2014.04.009
23. Григорьева В.Н. Когнитивная реабилитация – новое направление медицинской помощи больным с очаговыми поражениями головного мозга. Соврем. технол. в мед. 2010; 2: 95–9. / Grigor'eva V.N. Kognitivnaia reabilitatsiia – novoe napravlenie meditsinskoi pomoshchi bol'nym s ochagovymi porazheniiami golovnogo mozga. Sovrem. tekhnol. v med. 2010; 2: 95–9. [in Russian]
24. Tan T, Wang D, Huang J et al. Modulatory effects of acupuncture on brain networks in mild cognitive impairment patients. Neural Regen Res 2017; 12 (2): 250–8. DOI: 10.4103/1673-5374.200808
25. Moreira SV, Justi FR dos R, Moreira M. Can musical intervention improve memory in Alzheimer’s patients? Evidence from a systematic review. Dement Neuropsychol 2018; 12 (2): 133–42. DOI: 10.1590/1980-57642018dn12-020005
26. Satoh M, Ogawa J, Tokita T et al. The Effects of Physical Exercise with Music on Cognitive Function of Elderly People: Mihama-Kiho Project. PLoS ONE 2014; 9 (4): e95230. DOI: 10.1371/journal.pone.0095230
27. Федотчев А.И., Бондарь А.Т., Бахчина А.В. и др. Трансформация ЭЭГ-осцилляторов пациента в музыкоподобные сигналы при коррекции стресс-индуцированных функциональных состояний. Соврем. технол. в мед. 2016; 8 (1): 93–8. / Fedotchev A.I., Bondar' A.T., Bakhchina A.V. i dr. Transformatsiia EEG-ostsilliatorov patsienta v muzykopodobnye signaly pri korrektsii stress-indutsirovannykh funktsional'nykh sostoianii. Sovrem. tekhnol. v med. 2016; 8 (1): 93–8. [in Russian]
28. Anderson-Hanley C, Barcelos NM, Zimmerman EA et al. The Aerobic and Cognitive Exercise Study (ACES) for Community-Dwelling Older Adults With or At-Risk for Mild Cognitive Impairment (MCI): Neuropsychological, Neurobiological and Neuroimaging Outcomes of a Randomized Clinical Trial. Front Aging Neurosci 2018; 10: 76. DOI: 10.3389/fnagi.2018.00076
29. Newman-Tancredi A. Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and alpha 1/alpha 2-Adrenoceptor. J Pharmacol Exp Ther 2002; 303 (2): 805–14. DOI: 10.1124/jpet.102.039875
30. Peihua L, Jianqin W. Clinical Effects of Piribedil in Adjuvant Treatment of Parkinson’s Disease: A Meta-Analysis. Open Medicine 2018; 13: 270–7. DOI: 10.1515/med-2018-0041
31. Perez-Lloret S, Rascol O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs 2016; 30 (8): 703–17. DOI: 10.1007/s40263-016-0360-5
32. Pertovaara A, Haapalinna A, Sirvio J et al. Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist. CNS Drug Rev 2005; 11: 273–88.
33. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002; 41: 261–309.
34. Simon N, Micallef J, Reynier JC et al. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson’s disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study. Mov Disord 2005; 20: 803–9.
35. Rascol O, Azulay JP, Blin O et al. Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study. Mov Disord 2010; 25: 368–76.
36. Schück S, Bentué-Ferrer D, Kleinermans D et al. Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. Fundam Clin Pharmacol 2002; 16 (1): 57–65.
37. Castro-Caldas A, Delwaide P, Jost W et al. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord 2006; 21 (4): 500–9.
38. Peretti CS, Gierski F, Harrois S. Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil. Psychopharmacology (Berl) 2004; 176 (2): 175–81.
39. Gierski F, Peretti CS, Ergis AM. Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 262–8.
40. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol 1992; 239 (Suppl. 1): S13–6.
41. Cooper C, Li R, Lyketsos C, Livingston G. A systematic review of treatments for Mild Cognitive Impairment. Br J Psychiatry: J Mental Sci 2013; 203 (3): 255–64. DOI: 10.1192/bjp.bp.113.127811.
42. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 158 (9): 1517–9.
43. Захаров В.В. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврол. журн. 2006; 11: 27–32. / Zakharov V.V. Vserossiiskaia programma issledovanii epidemiologii i terapii kognitivnykh rasstroistv v pozhilom vozraste ("Prometei"). Nevrol. zhurn. 2006; 11: 27–32. [in Russian]
44. Яхно Н.Н., Захаров В.В., Страчунская Е.Я. и др. Лечение недементных когнитивных нарушений у пациентов с артериальной гипертензией и церебральным атеросклерозом (по данным российского мультицентрового исследования «ФУЭТЕ»). Неврол. журн. 2012; 4: 49–55. / Iakhno N.N., Zakharov V.V., Strachunskaia E.Ia. i dr. Lechenie nedementnykh kognitivnykh narushenii u patsientov s arterial'noi gipertenziei i tserebral'nym aterosklerozom (po dannym rossiiskogo mul'titsentrovogo issledovaniia "FUETE". Nevrol. zhurn. 2012; 4: 49–55. [in Russian]
45. Боголепова А., Чуканова Е. Пирибедил в лечении пациентов с хронической ишемией мозга и когнитивными нарушениями. Врач. 2016; 4: 58–63. / Bogolepova A., Chukanova E. Piribedil v lechenii patsientov s khronicheskoi ishemiei mozga i kognitivnymi narusheniiami. Vrach. 2016; 4: 58–63. [in Russian]
46. Ганькина О.А., Васенина Е.Е., Васенина Е.Д. и др. Влияние Пирибедила на умеренные когнитивные нарушения при дисциркуляторной энцефалопатии. Журн. неврологии и психиатрии им. C.C.Корсакова. 2014; 114 (6–2): 62–7. / Gan'kina O.A., Vasenina E.E., Vasenina E.D. i dr. Vliianie Piribedila na umerennye kognitivnye narusheniia pri distsirkuliatornoi entsefalopatii. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2014; 114 (6–2): 62–7. [in Russian]
47. Захаров В.В. Эволюция когнитивного дефицита: легкие и умеренные когнитивные нарушения. Неврология, нейропсихиатрия, психосоматика. 2012; 2: 16–21. / Zakharov V.V. Evoliutsiia kognitivnogo defitsita: legkie i umerennye kognitivnye narusheniia. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2012; 2: 16–21. [in Russian]
48. Захаров В.В., Громова Д.О. Современные подходы к ведению пациентов с умеренными когнитивными нарушениями. Журн. неврологии и психиатрии им. C.C.Корсакова. 2017; 117 (3): 107–12. DOI: 10.17116/jnevro201711731107-112 / Zakharov V.V., Gromova D.O. Sovremennye podkhody k vedeniiu patsientov s umerennymi kognitivnymi narusheniiami. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2017; 117 (3): 107–12. DOI: 10.17116/jnevro201711731107-112 [in Russian]
49. Захаров В.В., Локшина А.Б. Применение препарата «Проноран» (пирибедил) при легких когнитивных расстройствах у пожилых больных с дисциркуляторной энцефалопатией. Неврол. журнал. 2004; 9 (2): 30–5. / Zakharov V.V., Lokshina A.B. Primenenie preparata "Pronoran" (piribedil) pri legkikh kognitivnykh rasstroistvakh u pozhilykh bol'nykh s distsirkuliatornoi entsefalopatiei. Nevrol. zhurnal. 2004; 9 (2): 30–5. [in Russian]
50. Пилипович А.А. Нарушения памяти и роль Пронорана в их коррекции. Эффективная фармакотерапия. 2016; 9: 8–17. / Pilipovich A.A. Narusheniia pamiati i rol' Pronorana v ikh korrektsii. Effektivnaia farmakoterapiia. 2016; 9: 8–17. [in Russian]
2. Allain H, Akwa Y, Lacomblez L et al. Impaired cognition and attention in adults: pharmacological management strategies. Neuropsychiatr Dis Treat 2007; 3 (1): 103–16. DOI: 10.2147/nedt.2007.3.1.103
3. Kirova AM, Bays RB, Lagalwar S. Working memory and executive function decline across normal aging, mild cognitive impairment, and Alzheimer's disease. Biomed Res Int 2015; 2015: 748212. DOI: 10.1155/2015/748212
4. Iakhno N.N., Zakharov V.V. Legkie kognitivnye narusheniia v pozhilom vozraste. Nevrol. zhurn. 2004; 1: 4–8. [in Russian]
5. Gekht I.A., Artem'eva G.B. Postarenie naseleniia i programmy modernizatsii zdravookhraneniia. Klin. gerontologiia. 2013; 19 (7–8): 37–8. [in Russian]
6. Wimo A, Guerchet M, Ali G et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement 2017; 13 (1): 1–7. DOI: 10.1016/j.jalz.2016.07.150
7. Vladimirova O.N., Bashkireva A.S., Korobov M.V. i dr. Mediko-sotsial'nye aspekty pervichnoi invalidnosti u lits trudosposobnogo i starshe trudosposobnogo vozrasta v Rossiiskoi Federatsii. Uspekhi gerontologii. 2017; 30 (4): 498–504. [in Russian]
8. Smirnov A.A., Gustov A.V., Kopishinskaia S.V., Antonova V.A. Preddementnye sostoianiia i dementsiia u lits molodogo vozrasta. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2014; 2: 41–3. [in Russian]
9. Radiuk M.A., Svetozarskii S.N., Kopishinskaia S.V. Nemotornye proiavleniia bolezni Parkinsona. Med. al'manakh. 2014; 33 (3): 54–8. [in Russian]
10. Petersen SE, Sporns O. Brain Networks and Cognitive Architectures. Neuron 2015; 88 (1): 207–19. DOI: 10.1016/j.neuron.2015.09.027
11. Salavati B, Rajji TK, Price R et al. Imaging-Based Neurochemistry in Schizophrenia: A Systematic Review and Implications for Dysfunctional Long-Term Potentiation. Schizophr Bull 2015; 41 (1): 44–56. DOI: 10.1093/schbul/sbu132
12. Zakharov V., Milovanova O., Grishina D. i dr. Piribedil v lechenii legkikh i umerennykh kognitivnykh narushenii. Vrach. 2017; 3: 32–7. [in Russian]
13. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectrums 2014; 19 (2): 121–33. DOI: 10.1017/S1092852913000540
14. Braga AC, Carreiro LRR, Tafla TL et al. Cognitive and behavioral profile of Williams Syndrome toddlers. Codas 2018; 30 (4): e20170188. DOI: 10.1590/2317-1782/
20182017188
15. Whitton L, Apostolova G, Rieder D et al. Genes regulated by SATB2 during neurodevelopment contribute to schizophrenia and educational attainment. PLoS Genet 2018; 14 (7): e1007515. DOI: 10.1371/journal.pgen.1007515
16. Callier SL, Bonham VL. Taking a Stand: The Genetics Community's Responsibility for Intelligence Research. Hastings Cent Rep 2015; 45 (Suppl. 5): S54-8. DOI: 10.1002/hast.500
17. Roberts D. Can Research on the Genetics of Intelligence Be "Socially Neutral"? Hastings Cent Rep 2015; 45 (Suppl. 5): S50-3. DOI: 10.1002/hast.499
18. Aridi YS, Walker JL, Wright ORL. The Association between the Mediterranean Dietary Pattern and Cognitive Health: A Systematic Review. Nutrients 2017; 9 (7): 674. DOI: 10.3390/nu9070674
19. Zakharov V.V., Vakhnina N.V., Gromova D.O. i dr. Klinicheskii spektr nedementnykh kognitivnykh rasstroistv: sub"ektivnye, legkie i umerennye narusheniia. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2015; 7 (4): 83–91. [in Russian]
20. Pilipovich A.A. Moderate cognitive disorders: the role of Pronoran in their correction. Consilium Medicum. 2017; 19 (2.3. Neurology and Rheumatology): 38–42. [in Russian]
21. Svetozarskii S.N., Kopishinskaia S.V. Opticheskaia kogerentnaia tomografiia setchatki pri neirodegenerativnykh zabolevaniiakh (obzor). Sovrem. tekhnol. v med. 2015; 7 (1): 116–23. [in Russian]
22. Coyle H, Traynor V, Solowij N. Computerized and virtual reality cognitive training for individuals at high risk of cognitive decline: systematic review of the literature. Am J Geriatr Psychiatry 2015; 23 (4): 335–59. DOI: 10.1016/j.jagp.2014.04.009
23. Grigor'eva V.N. Kognitivnaia reabilitatsiia – novoe napravlenie meditsinskoi pomoshchi bol'nym s ochagovymi porazheniiami golovnogo mozga. Sovrem. tekhnol. v med. 2010; 2: 95–9. [in Russian]
24. Tan T, Wang D, Huang J et al. Modulatory effects of acupuncture on brain networks in mild cognitive impairment patients. Neural Regen Res 2017; 12 (2): 250–8. DOI: 10.4103/1673-5374.200808
25. Moreira SV, Justi FR dos R, Moreira M. Can musical intervention improve memory in Alzheimer’s patients? Evidence from a systematic review. Dement Neuropsychol 2018; 12 (2): 133–42. DOI: 10.1590/1980-57642018dn12-020005
26. Satoh M, Ogawa J, Tokita T et al. The Effects of Physical Exercise with Music on Cognitive Function of Elderly People: Mihama-Kiho Project. PLoS ONE 2014; 9 (4): e95230. DOI: 10.1371/journal.pone.0095230
27. Fedotchev A.I., Bondar' A.T., Bakhchina A.V. i dr. Transformatsiia EEG-ostsilliatorov patsienta v muzykopodobnye signaly pri korrektsii stress-indutsirovannykh funktsional'nykh sostoianii. Sovrem. tekhnol. v med. 2016; 8 (1): 93–8. [in Russian]
28. Anderson-Hanley C, Barcelos NM, Zimmerman EA et al. The Aerobic and Cognitive Exercise Study (ACES) for Community-Dwelling Older Adults With or At-Risk for Mild Cognitive Impairment (MCI): Neuropsychological, Neurobiological and Neuroimaging Outcomes of a Randomized Clinical Trial. Front Aging Neurosci 2018; 10: 76. DOI: 10.3389/fnagi.2018.00076
29. Newman-Tancredi A. Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and alpha 1/alpha 2-Adrenoceptor. J Pharmacol Exp Ther 2002; 303 (2): 805–14. DOI: 10.1124/jpet.102.039875
30. Peihua L, Jianqin W. Clinical Effects of Piribedil in Adjuvant Treatment of Parkinson’s Disease: A Meta-Analysis. Open Medicine 2018; 13: 270–7. DOI: 10.1515/med-2018-0041
31. Perez-Lloret S, Rascol O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs 2016; 30 (8): 703–17. DOI: 10.1007/s40263-016-0360-5
32. Pertovaara A, Haapalinna A, Sirvio J et al. Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist. CNS Drug Rev 2005; 11: 273–88.
33. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002; 41: 261–309.
34. Simon N, Micallef J, Reynier JC et al. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson’s disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study. Mov Disord 2005; 20: 803–9.
35. Rascol O, Azulay JP, Blin O et al. Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study. Mov Disord 2010; 25: 368–76.
36. Schück S, Bentué-Ferrer D, Kleinermans D et al. Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. Fundam Clin Pharmacol 2002; 16 (1): 57–65.
37. Castro-Caldas A, Delwaide P, Jost W et al. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord 2006; 21 (4): 500–9.
38. Peretti CS, Gierski F, Harrois S. Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil. Psychopharmacology (Berl) 2004; 176 (2): 175–81.
39. Gierski F, Peretti CS, Ergis AM. Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 262–8.
40. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol 1992; 239 (Suppl. 1): S13–6.
41. Cooper C, Li R, Lyketsos C, Livingston G. A systematic review of treatments for Mild Cognitive Impairment. Br J Psychiatry: J Mental Sci 2013; 203 (3): 255–64. DOI: 10.1192/bjp.bp.113.127811.
42. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 158 (9): 1517–9.
43. Zakharov V.V. Vserossiiskaia programma issledovanii epidemiologii i terapii kognitivnykh rasstroistv v pozhilom vozraste ("Prometei"). Nevrol. zhurn. 2006; 11: 27–32. [in Russian]
44. Iakhno N.N., Zakharov V.V., Strachunskaia E.Ia. i dr. Lechenie nedementnykh kognitivnykh narushenii u patsientov s arterial'noi gipertenziei i tserebral'nym aterosklerozom (po dannym rossiiskogo mul'titsentrovogo issledovaniia "FUETE". Nevrol. zhurn. 2012; 4: 49–55. [in Russian]
45. Bogolepova A., Chukanova E. Piribedil v lechenii patsientov s khronicheskoi ishemiei mozga i kognitivnymi narusheniiami. Vrach. 2016; 4: 58–63. [in Russian]
46. Gan'kina O.A., Vasenina E.E., Vasenina E.D. i dr. Vliianie Piribedila na umerennye kognitivnye narusheniia pri distsirkuliatornoi entsefalopatii. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2014; 114 (6–2): 62–7. [in Russian]
47. Zakharov V.V. Evoliutsiia kognitivnogo defitsita: legkie i umerennye kognitivnye narusheniia. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2012; 2: 16–21. [in Russian]
48. Zakharov V.V., Gromova D.O. Sovremennye podkhody k vedeniiu patsientov s umerennymi kognitivnymi narusheniiami. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2017; 117 (3): 107–12. DOI: 10.17116/jnevro201711731107-112 [in Russian]
49. Zakharov V.V., Lokshina A.B. Primenenie preparata "Pronoran" (piribedil) pri legkikh kognitivnykh rasstroistvakh u pozhilykh bol'nykh s distsirkuliatornoi entsefalopatiei. Nevrol. zhurnal. 2004; 9 (2): 30–5. [in Russian]
50. Pilipovich A.A. Narusheniia pamiati i rol' Pronorana v ikh korrektsii. Effektivnaia farmakoterapiia. 2016; 9: 8–17. [in Russian]
2. Allain H, Akwa Y, Lacomblez L et al. Impaired cognition and attention in adults: pharmacological management strategies. Neuropsychiatr Dis Treat 2007; 3 (1): 103–16. DOI: 10.2147/nedt.2007.3.1.103
3. Kirova AM, Bays RB, Lagalwar S. Working memory and executive function decline across normal aging, mild cognitive impairment, and Alzheimer's disease. Biomed Res Int 2015; 2015: 748212. DOI: 10.1155/2015/748212
4. Яхно Н.Н., Захаров В.В. Легкие когнитивные нарушения в пожилом возрасте. Неврол. журн. 2004; 1: 4–8. / Iakhno N.N., Zakharov V.V. Legkie kognitivnye narusheniia v pozhilom vozraste. Nevrol. zhurn. 2004; 1: 4–8. [in Russian]
5. Гехт И.А., Артемьева Г.Б. Постарение населения и программы модернизации здравоохранения. Клин. геронтология. 2013; 19 (7–8): 37–8. / Gekht I.A., Artem'eva G.B. Postarenie naseleniia i programmy modernizatsii zdravookhraneniia. Klin. gerontologiia. 2013; 19 (7–8): 37–8. [in Russian]
6. Wimo A, Guerchet M, Ali G et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement 2017; 13 (1): 1–7. DOI: 10.1016/j.jalz.2016.07.150
7. Владимирова О.Н., Башкирёва А.С., Коробов М.В. и др. Медико-социальные аспекты первичной инвалидности у лиц трудоспособного и старше трудоспособного возраста в Российской Федерации. Успехи геронтологии. 2017; 30 (4): 498–504. / Vladimirova O.N., Bashkireva A.S., Korobov M.V. i dr. Mediko-sotsial'nye aspekty pervichnoi invalidnosti u lits trudosposobnogo i starshe trudosposobnogo vozrasta v Rossiiskoi Federatsii. Uspekhi gerontologii. 2017; 30 (4): 498–504. [in Russian]
8. Смирнов А.А., Густов А.В., Копишинская С.В., Антонова В.А. Преддементные состояния и деменция у лиц молодого возраста. Неврология, нейропсихиатрия, психосоматика. 2014; 2: 41–3. / Smirnov A.A., Gustov A.V., Kopishinskaia S.V., Antonova V.A. Preddementnye sostoianiia i dementsiia u lits molodogo vozrasta. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2014; 2: 41–3. [in Russian]
9. Радюк М.А., Светозарский С.Н., Копишинская С.В. Немоторные проявления болезни Паркинсона. Мед. альманах. 2014; 33 (3): 54–8. / Radiuk M.A., Svetozarskii S.N., Kopishinskaia S.V. Nemotornye proiavleniia bolezni Parkinsona. Med. al'manakh. 2014; 33 (3): 54–8. [in Russian]
10. Petersen SE, Sporns O. Brain Networks and Cognitive Architectures. Neuron 2015; 88 (1): 207–19. DOI: 10.1016/j.neuron.2015.09.027
11. Salavati B, Rajji TK, Price R et al. Imaging-Based Neurochemistry in Schizophrenia: A Systematic Review and Implications for Dysfunctional Long-Term Potentiation. Schizophr Bull 2015; 41 (1): 44–56. DOI: 10.1093/schbul/sbu132
12. Захаров В., Милованова О., Гришина Д. и др. Пирибедил в лечении легких и умеренных когнитивных нарушений. Врач. 2017; 3: 32–7. / Zakharov V., Milovanova O., Grishina D. i dr. Piribedil v lechenii legkikh i umerennykh kognitivnykh narushenii. Vrach. 2017; 3: 32–7. [in Russian]
13. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectrums 2014; 19 (2): 121–33. DOI: 10.1017/S1092852913000540
14. Braga AC, Carreiro LRR, Tafla TL et al. Cognitive and behavioral profile of Williams Syndrome toddlers. Codas 2018; 30 (4): e20170188. DOI: 10.1590/2317-1782/
20182017188
15. Whitton L, Apostolova G, Rieder D et al. Genes regulated by SATB2 during neurodevelopment contribute to schizophrenia and educational attainment. PLoS Genet 2018; 14 (7): e1007515. DOI: 10.1371/journal.pgen.1007515
16. Callier SL, Bonham VL. Taking a Stand: The Genetics Community's Responsibility for Intelligence Research. Hastings Cent Rep 2015; 45 (Suppl. 5): S54-8. DOI: 10.1002/hast.500
17. Roberts D. Can Research on the Genetics of Intelligence Be "Socially Neutral"? Hastings Cent Rep 2015; 45 (Suppl. 5): S50-3. DOI: 10.1002/hast.499
18. Aridi YS, Walker JL, Wright ORL. The Association between the Mediterranean Dietary Pattern and Cognitive Health: A Systematic Review. Nutrients 2017; 9 (7): 674. DOI: 10.3390/nu9070674
19. Захаров В.В., Вахнина Н.В., Громова Д.О. и др. Клинический спектр недементных когнитивных расстройств: субъективные, легкие и умеренные нарушения. Неврология, нейропсихиатрия, психосоматика. 2015; 7 (4): 83–91. / Zakharov V.V., Vakhnina N.V., Gromova D.O. i dr. Klinicheskii spektr nedementnykh kognitivnykh rasstroistv: sub"ektivnye, legkie i umerennye narusheniia. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2015; 7 (4): 83–91. [in Russian]
20. Пилипович А.А. Умеренные когнитивные расстройства: роль Пронорана в их коррекции. Consilium Medicum. 2017; 19 (2.3. Неврология и Ревматология): 38–42. / Pilipovich A.A. Moderate cognitive disorders: the role of Pronoran in their correction. Consilium Medicum. 2017; 19 (2.3. Neurology and Rheumatology): 38–42. [in Russian]
21. Светозарский С.Н., Копишинская С.В. Оптическая когерентная томография сетчатки при нейродегенеративных заболеваниях (обзор). Соврем. технол. в мед. 2015; 7 (1): 116–23. / Svetozarskii S.N., Kopishinskaia S.V. Opticheskaia kogerentnaia tomografiia setchatki pri neirodegenerativnykh zabolevaniiakh (obzor). Sovrem. tekhnol. v med. 2015; 7 (1): 116–23. [in Russian]
22. Coyle H, Traynor V, Solowij N. Computerized and virtual reality cognitive training for individuals at high risk of cognitive decline: systematic review of the literature. Am J Geriatr Psychiatry 2015; 23 (4): 335–59. DOI: 10.1016/j.jagp.2014.04.009
23. Григорьева В.Н. Когнитивная реабилитация – новое направление медицинской помощи больным с очаговыми поражениями головного мозга. Соврем. технол. в мед. 2010; 2: 95–9. / Grigor'eva V.N. Kognitivnaia reabilitatsiia – novoe napravlenie meditsinskoi pomoshchi bol'nym s ochagovymi porazheniiami golovnogo mozga. Sovrem. tekhnol. v med. 2010; 2: 95–9. [in Russian]
24. Tan T, Wang D, Huang J et al. Modulatory effects of acupuncture on brain networks in mild cognitive impairment patients. Neural Regen Res 2017; 12 (2): 250–8. DOI: 10.4103/1673-5374.200808
25. Moreira SV, Justi FR dos R, Moreira M. Can musical intervention improve memory in Alzheimer’s patients? Evidence from a systematic review. Dement Neuropsychol 2018; 12 (2): 133–42. DOI: 10.1590/1980-57642018dn12-020005
26. Satoh M, Ogawa J, Tokita T et al. The Effects of Physical Exercise with Music on Cognitive Function of Elderly People: Mihama-Kiho Project. PLoS ONE 2014; 9 (4): e95230. DOI: 10.1371/journal.pone.0095230
27. Федотчев А.И., Бондарь А.Т., Бахчина А.В. и др. Трансформация ЭЭГ-осцилляторов пациента в музыкоподобные сигналы при коррекции стресс-индуцированных функциональных состояний. Соврем. технол. в мед. 2016; 8 (1): 93–8. / Fedotchev A.I., Bondar' A.T., Bakhchina A.V. i dr. Transformatsiia EEG-ostsilliatorov patsienta v muzykopodobnye signaly pri korrektsii stress-indutsirovannykh funktsional'nykh sostoianii. Sovrem. tekhnol. v med. 2016; 8 (1): 93–8. [in Russian]
28. Anderson-Hanley C, Barcelos NM, Zimmerman EA et al. The Aerobic and Cognitive Exercise Study (ACES) for Community-Dwelling Older Adults With or At-Risk for Mild Cognitive Impairment (MCI): Neuropsychological, Neurobiological and Neuroimaging Outcomes of a Randomized Clinical Trial. Front Aging Neurosci 2018; 10: 76. DOI: 10.3389/fnagi.2018.00076
29. Newman-Tancredi A. Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and alpha 1/alpha 2-Adrenoceptor. J Pharmacol Exp Ther 2002; 303 (2): 805–14. DOI: 10.1124/jpet.102.039875
30. Peihua L, Jianqin W. Clinical Effects of Piribedil in Adjuvant Treatment of Parkinson’s Disease: A Meta-Analysis. Open Medicine 2018; 13: 270–7. DOI: 10.1515/med-2018-0041
31. Perez-Lloret S, Rascol O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs 2016; 30 (8): 703–17. DOI: 10.1007/s40263-016-0360-5
32. Pertovaara A, Haapalinna A, Sirvio J et al. Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist. CNS Drug Rev 2005; 11: 273–88.
33. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002; 41: 261–309.
34. Simon N, Micallef J, Reynier JC et al. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson’s disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study. Mov Disord 2005; 20: 803–9.
35. Rascol O, Azulay JP, Blin O et al. Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study. Mov Disord 2010; 25: 368–76.
36. Schück S, Bentué-Ferrer D, Kleinermans D et al. Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. Fundam Clin Pharmacol 2002; 16 (1): 57–65.
37. Castro-Caldas A, Delwaide P, Jost W et al. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord 2006; 21 (4): 500–9.
38. Peretti CS, Gierski F, Harrois S. Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil. Psychopharmacology (Berl) 2004; 176 (2): 175–81.
39. Gierski F, Peretti CS, Ergis AM. Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 262–8.
40. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol 1992; 239 (Suppl. 1): S13–6.
41. Cooper C, Li R, Lyketsos C, Livingston G. A systematic review of treatments for Mild Cognitive Impairment. Br J Psychiatry: J Mental Sci 2013; 203 (3): 255–64. DOI: 10.1192/bjp.bp.113.127811.
42. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 158 (9): 1517–9.
43. Захаров В.В. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврол. журн. 2006; 11: 27–32. / Zakharov V.V. Vserossiiskaia programma issledovanii epidemiologii i terapii kognitivnykh rasstroistv v pozhilom vozraste ("Prometei"). Nevrol. zhurn. 2006; 11: 27–32. [in Russian]
44. Яхно Н.Н., Захаров В.В., Страчунская Е.Я. и др. Лечение недементных когнитивных нарушений у пациентов с артериальной гипертензией и церебральным атеросклерозом (по данным российского мультицентрового исследования «ФУЭТЕ»). Неврол. журн. 2012; 4: 49–55. / Iakhno N.N., Zakharov V.V., Strachunskaia E.Ia. i dr. Lechenie nedementnykh kognitivnykh narushenii u patsientov s arterial'noi gipertenziei i tserebral'nym aterosklerozom (po dannym rossiiskogo mul'titsentrovogo issledovaniia "FUETE". Nevrol. zhurn. 2012; 4: 49–55. [in Russian]
45. Боголепова А., Чуканова Е. Пирибедил в лечении пациентов с хронической ишемией мозга и когнитивными нарушениями. Врач. 2016; 4: 58–63. / Bogolepova A., Chukanova E. Piribedil v lechenii patsientov s khronicheskoi ishemiei mozga i kognitivnymi narusheniiami. Vrach. 2016; 4: 58–63. [in Russian]
46. Ганькина О.А., Васенина Е.Е., Васенина Е.Д. и др. Влияние Пирибедила на умеренные когнитивные нарушения при дисциркуляторной энцефалопатии. Журн. неврологии и психиатрии им. C.C.Корсакова. 2014; 114 (6–2): 62–7. / Gan'kina O.A., Vasenina E.E., Vasenina E.D. i dr. Vliianie Piribedila na umerennye kognitivnye narusheniia pri distsirkuliatornoi entsefalopatii. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2014; 114 (6–2): 62–7. [in Russian]
47. Захаров В.В. Эволюция когнитивного дефицита: легкие и умеренные когнитивные нарушения. Неврология, нейропсихиатрия, психосоматика. 2012; 2: 16–21. / Zakharov V.V. Evoliutsiia kognitivnogo defitsita: legkie i umerennye kognitivnye narusheniia. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2012; 2: 16–21. [in Russian]
48. Захаров В.В., Громова Д.О. Современные подходы к ведению пациентов с умеренными когнитивными нарушениями. Журн. неврологии и психиатрии им. C.C.Корсакова. 2017; 117 (3): 107–12. DOI: 10.17116/jnevro201711731107-112 / Zakharov V.V., Gromova D.O. Sovremennye podkhody k vedeniiu patsientov s umerennymi kognitivnymi narusheniiami. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2017; 117 (3): 107–12. DOI: 10.17116/jnevro201711731107-112 [in Russian]
49. Захаров В.В., Локшина А.Б. Применение препарата «Проноран» (пирибедил) при легких когнитивных расстройствах у пожилых больных с дисциркуляторной энцефалопатией. Неврол. журнал. 2004; 9 (2): 30–5. / Zakharov V.V., Lokshina A.B. Primenenie preparata "Pronoran" (piribedil) pri legkikh kognitivnykh rasstroistvakh u pozhilykh bol'nykh s distsirkuliatornoi entsefalopatiei. Nevrol. zhurnal. 2004; 9 (2): 30–5. [in Russian]
50. Пилипович А.А. Нарушения памяти и роль Пронорана в их коррекции. Эффективная фармакотерапия. 2016; 9: 8–17. / Pilipovich A.A. Narusheniia pamiati i rol' Pronorana v ikh korrektsii. Effektivnaia farmakoterapiia. 2016; 9: 8–17. [in Russian]
________________________________________________
2. Allain H, Akwa Y, Lacomblez L et al. Impaired cognition and attention in adults: pharmacological management strategies. Neuropsychiatr Dis Treat 2007; 3 (1): 103–16. DOI: 10.2147/nedt.2007.3.1.103
3. Kirova AM, Bays RB, Lagalwar S. Working memory and executive function decline across normal aging, mild cognitive impairment, and Alzheimer's disease. Biomed Res Int 2015; 2015: 748212. DOI: 10.1155/2015/748212
4. Iakhno N.N., Zakharov V.V. Legkie kognitivnye narusheniia v pozhilom vozraste. Nevrol. zhurn. 2004; 1: 4–8. [in Russian]
5. Gekht I.A., Artem'eva G.B. Postarenie naseleniia i programmy modernizatsii zdravookhraneniia. Klin. gerontologiia. 2013; 19 (7–8): 37–8. [in Russian]
6. Wimo A, Guerchet M, Ali G et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement 2017; 13 (1): 1–7. DOI: 10.1016/j.jalz.2016.07.150
7. Vladimirova O.N., Bashkireva A.S., Korobov M.V. i dr. Mediko-sotsial'nye aspekty pervichnoi invalidnosti u lits trudosposobnogo i starshe trudosposobnogo vozrasta v Rossiiskoi Federatsii. Uspekhi gerontologii. 2017; 30 (4): 498–504. [in Russian]
8. Smirnov A.A., Gustov A.V., Kopishinskaia S.V., Antonova V.A. Preddementnye sostoianiia i dementsiia u lits molodogo vozrasta. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2014; 2: 41–3. [in Russian]
9. Radiuk M.A., Svetozarskii S.N., Kopishinskaia S.V. Nemotornye proiavleniia bolezni Parkinsona. Med. al'manakh. 2014; 33 (3): 54–8. [in Russian]
10. Petersen SE, Sporns O. Brain Networks and Cognitive Architectures. Neuron 2015; 88 (1): 207–19. DOI: 10.1016/j.neuron.2015.09.027
11. Salavati B, Rajji TK, Price R et al. Imaging-Based Neurochemistry in Schizophrenia: A Systematic Review and Implications for Dysfunctional Long-Term Potentiation. Schizophr Bull 2015; 41 (1): 44–56. DOI: 10.1093/schbul/sbu132
12. Zakharov V., Milovanova O., Grishina D. i dr. Piribedil v lechenii legkikh i umerennykh kognitivnykh narushenii. Vrach. 2017; 3: 32–7. [in Russian]
13. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectrums 2014; 19 (2): 121–33. DOI: 10.1017/S1092852913000540
14. Braga AC, Carreiro LRR, Tafla TL et al. Cognitive and behavioral profile of Williams Syndrome toddlers. Codas 2018; 30 (4): e20170188. DOI: 10.1590/2317-1782/
20182017188
15. Whitton L, Apostolova G, Rieder D et al. Genes regulated by SATB2 during neurodevelopment contribute to schizophrenia and educational attainment. PLoS Genet 2018; 14 (7): e1007515. DOI: 10.1371/journal.pgen.1007515
16. Callier SL, Bonham VL. Taking a Stand: The Genetics Community's Responsibility for Intelligence Research. Hastings Cent Rep 2015; 45 (Suppl. 5): S54-8. DOI: 10.1002/hast.500
17. Roberts D. Can Research on the Genetics of Intelligence Be "Socially Neutral"? Hastings Cent Rep 2015; 45 (Suppl. 5): S50-3. DOI: 10.1002/hast.499
18. Aridi YS, Walker JL, Wright ORL. The Association between the Mediterranean Dietary Pattern and Cognitive Health: A Systematic Review. Nutrients 2017; 9 (7): 674. DOI: 10.3390/nu9070674
19. Zakharov V.V., Vakhnina N.V., Gromova D.O. i dr. Klinicheskii spektr nedementnykh kognitivnykh rasstroistv: sub"ektivnye, legkie i umerennye narusheniia. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2015; 7 (4): 83–91. [in Russian]
20. Pilipovich A.A. Moderate cognitive disorders: the role of Pronoran in their correction. Consilium Medicum. 2017; 19 (2.3. Neurology and Rheumatology): 38–42. [in Russian]
21. Svetozarskii S.N., Kopishinskaia S.V. Opticheskaia kogerentnaia tomografiia setchatki pri neirodegenerativnykh zabolevaniiakh (obzor). Sovrem. tekhnol. v med. 2015; 7 (1): 116–23. [in Russian]
22. Coyle H, Traynor V, Solowij N. Computerized and virtual reality cognitive training for individuals at high risk of cognitive decline: systematic review of the literature. Am J Geriatr Psychiatry 2015; 23 (4): 335–59. DOI: 10.1016/j.jagp.2014.04.009
23. Grigor'eva V.N. Kognitivnaia reabilitatsiia – novoe napravlenie meditsinskoi pomoshchi bol'nym s ochagovymi porazheniiami golovnogo mozga. Sovrem. tekhnol. v med. 2010; 2: 95–9. [in Russian]
24. Tan T, Wang D, Huang J et al. Modulatory effects of acupuncture on brain networks in mild cognitive impairment patients. Neural Regen Res 2017; 12 (2): 250–8. DOI: 10.4103/1673-5374.200808
25. Moreira SV, Justi FR dos R, Moreira M. Can musical intervention improve memory in Alzheimer’s patients? Evidence from a systematic review. Dement Neuropsychol 2018; 12 (2): 133–42. DOI: 10.1590/1980-57642018dn12-020005
26. Satoh M, Ogawa J, Tokita T et al. The Effects of Physical Exercise with Music on Cognitive Function of Elderly People: Mihama-Kiho Project. PLoS ONE 2014; 9 (4): e95230. DOI: 10.1371/journal.pone.0095230
27. Fedotchev A.I., Bondar' A.T., Bakhchina A.V. i dr. Transformatsiia EEG-ostsilliatorov patsienta v muzykopodobnye signaly pri korrektsii stress-indutsirovannykh funktsional'nykh sostoianii. Sovrem. tekhnol. v med. 2016; 8 (1): 93–8. [in Russian]
28. Anderson-Hanley C, Barcelos NM, Zimmerman EA et al. The Aerobic and Cognitive Exercise Study (ACES) for Community-Dwelling Older Adults With or At-Risk for Mild Cognitive Impairment (MCI): Neuropsychological, Neurobiological and Neuroimaging Outcomes of a Randomized Clinical Trial. Front Aging Neurosci 2018; 10: 76. DOI: 10.3389/fnagi.2018.00076
29. Newman-Tancredi A. Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and alpha 1/alpha 2-Adrenoceptor. J Pharmacol Exp Ther 2002; 303 (2): 805–14. DOI: 10.1124/jpet.102.039875
30. Peihua L, Jianqin W. Clinical Effects of Piribedil in Adjuvant Treatment of Parkinson’s Disease: A Meta-Analysis. Open Medicine 2018; 13: 270–7. DOI: 10.1515/med-2018-0041
31. Perez-Lloret S, Rascol O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs 2016; 30 (8): 703–17. DOI: 10.1007/s40263-016-0360-5
32. Pertovaara A, Haapalinna A, Sirvio J et al. Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist. CNS Drug Rev 2005; 11: 273–88.
33. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002; 41: 261–309.
34. Simon N, Micallef J, Reynier JC et al. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson’s disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study. Mov Disord 2005; 20: 803–9.
35. Rascol O, Azulay JP, Blin O et al. Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study. Mov Disord 2010; 25: 368–76.
36. Schück S, Bentué-Ferrer D, Kleinermans D et al. Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. Fundam Clin Pharmacol 2002; 16 (1): 57–65.
37. Castro-Caldas A, Delwaide P, Jost W et al. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord 2006; 21 (4): 500–9.
38. Peretti CS, Gierski F, Harrois S. Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil. Psychopharmacology (Berl) 2004; 176 (2): 175–81.
39. Gierski F, Peretti CS, Ergis AM. Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 262–8.
40. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol 1992; 239 (Suppl. 1): S13–6.
41. Cooper C, Li R, Lyketsos C, Livingston G. A systematic review of treatments for Mild Cognitive Impairment. Br J Psychiatry: J Mental Sci 2013; 203 (3): 255–64. DOI: 10.1192/bjp.bp.113.127811.
42. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 158 (9): 1517–9.
43. Zakharov V.V. Vserossiiskaia programma issledovanii epidemiologii i terapii kognitivnykh rasstroistv v pozhilom vozraste ("Prometei"). Nevrol. zhurn. 2006; 11: 27–32. [in Russian]
44. Iakhno N.N., Zakharov V.V., Strachunskaia E.Ia. i dr. Lechenie nedementnykh kognitivnykh narushenii u patsientov s arterial'noi gipertenziei i tserebral'nym aterosklerozom (po dannym rossiiskogo mul'titsentrovogo issledovaniia "FUETE". Nevrol. zhurn. 2012; 4: 49–55. [in Russian]
45. Bogolepova A., Chukanova E. Piribedil v lechenii patsientov s khronicheskoi ishemiei mozga i kognitivnymi narusheniiami. Vrach. 2016; 4: 58–63. [in Russian]
46. Gan'kina O.A., Vasenina E.E., Vasenina E.D. i dr. Vliianie Piribedila na umerennye kognitivnye narusheniia pri distsirkuliatornoi entsefalopatii. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2014; 114 (6–2): 62–7. [in Russian]
47. Zakharov V.V. Evoliutsiia kognitivnogo defitsita: legkie i umerennye kognitivnye narusheniia. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2012; 2: 16–21. [in Russian]
48. Zakharov V.V., Gromova D.O. Sovremennye podkhody k vedeniiu patsientov s umerennymi kognitivnymi narusheniiami. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2017; 117 (3): 107–12. DOI: 10.17116/jnevro201711731107-112 [in Russian]
49. Zakharov V.V., Lokshina A.B. Primenenie preparata "Pronoran" (piribedil) pri legkikh kognitivnykh rasstroistvakh u pozhilykh bol'nykh s distsirkuliatornoi entsefalopatiei. Nevrol. zhurnal. 2004; 9 (2): 30–5. [in Russian]
50. Pilipovich A.A. Narusheniia pamiati i rol' Pronorana v ikh korrektsii. Effektivnaia farmakoterapiia. 2016; 9: 8–17. [in Russian]
Авторы
С.В.Копишинская, С.Н.Светозарский
ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России. 603000, Россия, Нижний Новгород, пл. Минина и Пожарского, д. 10/1
*kopishinskaya@gmail.com
Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation. 603005, Russian Federation, Nizhny Novgorod, pl. Minina and Pozharskogo, d. 10/1
*kopishinskaya@gmail.com
ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России. 603000, Россия, Нижний Новгород, пл. Минина и Пожарского, д. 10/1
*kopishinskaya@gmail.com
________________________________________________
Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation. 603005, Russian Federation, Nizhny Novgorod, pl. Minina and Pozharskogo, d. 10/1
*kopishinskaya@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.